Premium
Novel fully human anti‐CD47 antibodies stimulate phagocytosis and promote elimination of AML cells
Author(s) -
Wang Chaoyu,
Sun Chengtao,
Li Mengzhen,
Xia Bing,
Wang Yi,
Zhang Li,
Zhang Yanyan,
Wang Juan,
Sun Feifei,
Lu Suying,
Zhu Jia,
Huang Junting,
Zhang Yizhuo
Publication year - 2021
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.30163
Subject(s) - cd47 , phagocytosis , monoclonal antibody , antibody , in vivo , myeloid leukemia , bone marrow , immunology , in vitro , leukemia , cancer research , myeloid , medicine , biology , biochemistry , microbiology and biotechnology
Although most patients with acute myeloid leukemia (AML) enter remission after induction chemotherapy, the risk of relapse remains considerable. Therefore, some novel therapeutic strategies are still required. This study found that the overexpression of CD47 on AML cells was at least twofold more than that on normal bone marrow (NBM) cells in 81% (17/21) of the investigated patients; no patients had lower expression level of CD47 compared with healthy donors. The study also demonstrated that blocking the CD47/SIRPα (signal regulatory protein α) signal with the established novel fully human anti‐CD47 monoclonal antibodies increased the phagocytosis of AML cells by macrophages in vitro. Furthermore, in vivo experiments showed that the novel fully human anti‐CD47 monoclonal antibodies could significantly prolong the survival time of mice. Overall, the novel fully human anti‐CD47 antibodies could block CD47/SIRPα interaction, increase macrophage‐mediated phagocytosis, and enhance the elimination of AML cells.